Full-Time

Buyer/Planner

Updated on 7/12/2026

Illumina

Illumina

5,001-10,000 employees

Accelerates genomics startups through funding

No salary listed

Bengaluru, Karnataka, India

In Person

On-site in Bengaluru, Karnataka, India; no remote option stated.

Category
Operations & Logistics (1)
Required Skills
Supply Chain Management
Inventory Management
SAP Products
Excel/Numbers/Sheets

People at Illumina

People at Illumina who can refer or advise you

Requirements
  • Experience in Global suppliers and stakeholder management
  • SAP ECC MM module and Material Requirements Planning knowledge
  • Ariba SCC knowledge preferred
  • Thorough knowledge of direct procurement, vendor relations, and inventory management
  • Familiar with GMPs, product specifications incoming inspection procedures
  • Effective verbal and written communication, analytical and interpersonal skills
  • Strong problem solving, organizational skills, detail oriented
  • Strong influencing and negotiating skills
  • Strong knowledge of Microsoft Excel and Outlook
  • Typically requires a Bachelor’s degree and a minimum of 3-5 years of related experience; or 2 years and a Master’s degree; or equivalent work experience
Responsibilities
  • Reviews and analyzes purchase requisitions. Coordinates purchasing activities with manufacturing, planning and engineering departments to acquire inventory in a cost effective and timely manner.
  • Processes purchase requisitions, purchase change orders and requests for quotes to suppliers.
  • Responsible for procurement business system data input and integrity; creates and maintains bills of material and parts/commodities numbers in supply chain management or other Enterprisewide systems.
  • Participates in maximizing the procurement teams' changes, part parameters; quote table maintenance, supplier database information, error report analysis, and part number/supplier code information.
  • Performs cost analysis and volume planning for major commodities (e.g., materials, components, equipment and services).
  • Monitors the cost, schedule and scope of assigned subcontracts to negotiate highest quality at best value.
  • Develops new supply sources where vendors and suppliers are no longer competitive.
  • May recommend cost saving proposals including make-versus-buy analysis or alternative sourcing.
  • Interacts closely with suppliers and QA to resolve quality issues.
  • Works with management to address all aspects of commodity management, including procurement support, commodity business plans, market trends assessment, pricing, and product availability.
  • Applies company policies and procedures to resolve a variety of issues.
  • Determines a course of action based on guidelines. Modifies processes and methods as required.
  • Works on assignments of moderate scope where problem solving requires application of learned techniques.
  • Builds productive working relationships internally and externally.
  • Provides standard professional guidance and collaborates to resolve mutual problems.
  • Works autonomously and receives little instruction on day-to-day work/new assignments.
  • Exercises judgment within defined procedures and practices to determine appropriate action.
  • Owns the assigned suppliers and parts for the timely delivery of materials to the manufacturing site to satisfy requirements for manufacturing and spare parts.
  • Maintains effective collaboration with suppliers to ensure no disruption to manufacturing and escalates internally and externally for support as needed.
  • Performs management of Supplier lead times, safety stock, expedites, Supplier Change Notifications (SCNs) and supplier collaboration of delivery reschedules.
  • Collaborates with Planning, Quality, Engineering, Manufacturing teams and Suppliers on material quality issues.
  • May facilitate virtual meetings, publish notes/actions.
  • Collaborates with Sourcing, used SAP material settings and executes purchase orders to optimize pricing tiers, minimum order quantities, supplier capacity plans.
  • Coordinates with supplier, Quality and Warehousing on RMA return to vendor actions including repair and refurbishment.
  • Works with a PLM (Product Lifecycle Management) system with access to specifications, part diagrams, work instructions, etc..
  • Works with Reliance / ETQ quality management system, actions assignments, documents changes.
  • Responsible for procurement business system data input and integrity, is champion for Suppliers using our Ariba B2B solutions, portals and collaboration tools.
  • Ensures accuracy of confirmed delivery dates for materials on our SAP system and negotiates with suppliers as necessary to expedite or push out deliveries.
  • Drives on time delivery, inventory turnover, requisition conversion and other key performance indicators (KPIs) for the assigned suppliers.
  • Secures part certifications as appropriate from suppliers for successful global distribution of spare parts.
  • May recommend cost saving proposals to suppliers in collaboration with Sourcing teams.
Desired Qualifications
  • Experience in Ariba B2B solutions, portals and collaboration tools

Illumina Accelerator helps create and grow genomics startups by partnering with venture investors and entrepreneurs as part of Illumina for Startups. It runs as a company-creation engine co-located with Illumina’s R&D sites in the San Francisco Bay Area and Cambridge, UK, offering mentorship, resources, and access to Illumina’s technology and networks. Its edge comes from Illumina’s sequencing tech, R&D resources, and a global network, plus a track record of 68 funded startups that have raised over $1 billion. The goal is to support ideas turning into market-ready genomics products and companies.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1998

People at Illumina

People at Illumina who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • StrataMap enables high-throughput spatial transcriptomics with 2,000+ samples/year throughput for oncology and neuroscience research.
  • First whole-transcriptome spatial datasets from BIDMC and Cancer Research UK validate StrataMap's research utility in human tissues.
  • FFPE-specific StrataMap version targeted for 2027 will expand clinical sample accessibility and oncology diagnostic applications.

What critics are saying

  • Roche Axelios 1 undercuts NovaSeq X by 50% with $150 per-genome cost, threatening 70% market share in 6-12 months.
  • Axelios 1 delivers 16 genomes in 4 hours with duplex quality, enabling Roche to capture spatial and single-cell customers faster.
  • Axelios 1 supports FFPE, cfDNA, and genomic DNA at launch, eliminating Illumina's need for specialized modules and lowering switching costs.

What makes Illumina unique

  • Illumina launched StrataMap Spatial in June 2026, offering true single-cell resolution with 2x more genes per sample.
  • StrataMap runs on existing NovaSeq/NextSeq instruments, enabling accessible spatial biology entry without specialized hardware.
  • StrataMap includes DRAGEN and Connected Multiomics software for machine-learning-driven cell segmentation and multiomic integration.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-2%
Oregon Capital Insider
May 21st, 2026
David P. King elected to Illumina's Board of Directors.

David P. King elected to Illumina's Board of Directors. PR Newswire Today at 1:15pm PDT Former Labcorp Chairman and CEO brings deep healthcare, diagnostics, and clinical expertise to Illumina's Board SAN DIEGO, May 21, 2026 /PRNewswire/ - Illumina, Inc. (NASDAQ: ILMN) today confirmed the election of David P. King to its Board of Directors, effective immediately following the company's annual meeting of shareholders. Mr. King's election marks an important addition to Illumina's Board as the company accelerates its clinical strategy to integrate genomics more broadly into the standard of care. "We are delighted to welcome David to the Illumina Board," said Jacob Thaysen, chief executive officer of Illumina. "David brings deep regulatory knowledge, broad industry credibility, and the respect earned over decades at the forefront of healthcare and life sciences. Under his leadership at Labcorp, the company tripled in size through organic growth and strategic acquisitions. His perspective across diagnostics, healthcare delivery, and board governance will strengthen our ability to deliver long-term impact for patients, customers, and shareholders." Mr. King is the former Executive Chairman and Chief Executive Officer of Labcorp. Under his leadership, Labcorp entered the Fortune 500, and was recognized by Fortune as one of the World's Most Admired Companies. Mr. King joins the Board following the retirement of Frances Arnold, PhD, Robert S. Epstein, MD, and Gary S. Guthart, PhD, each of whom concluded distinguished tenures on the Board at the company's annual meeting. About David P. King David P. King was elected to Illumina's Board of Directors in 2026. Mr. King has extensive experience in the healthcare and life sciences sectors in executive and non-executive roles, including leading complex businesses at scale, driving operational excellence and commercial initiatives, and executing transformational change through M&A and organic growth. Mr. King served as Chair and Chief Executive Officer as well as Executive Chairman of Laboratory Corporation of America Holdings (Labcorp) from 2007 to 2019. He provides strategic advisory services across the healthcare ecosystem through KingMan LLC. Mr. King also serves as Chair of Privia Health Group, Inc., as a director of Smith & Nephew, and has served in board leadership roles across a range of healthcare companies, including as Chair of ZimVie (2022-2025) and as Non-Executive Chair of PathGroup, LGC Limited, and AmSurg. Earlier in his career, Mr. King was a partner at Hogan & Hartson LLP (now Hogan Lovells) and served as an Assistant U.S. Attorney for the District of Maryland. Mr. King received a B.A. from Princeton University and a J.D. from the University of Pennsylvania Law School. About Illumina Illumina is improving human health by unlocking the power of the genome. Its focus on innovation has established Oregon Capital Insider as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Its products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with Oregon Capital Insider on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube. Investors: Illumina Investor Relations 858-291-6421 [email protected] SOURCE Illumina, Inc. This is a paid placement. For further inquiries, please contact PR Newswire directly.

Mitalab Co., Ltd.
May 14th, 2026
Mitalab officially becomes A comprehensive distribution partner of Illumina.

Mitalab officially becomes A comprehensive distribution partner of Illumina. Dear Valued Partners and Customers, Mitalab is honored to announce a significant strategic milestone in its collaboration journey. Effective from May 13, 2026, Mitalab has officially become the comprehensive distributor of both Illumina's "IVD Diagnostics" and "RUO Research" product portfolios. Illumina is globally recognized as a leading innovator in genomic sequencing and biotechnology. Becoming an authorized distributor for both the IVD and RUO product lines not only marks a major advancement in the partnership between Mitalab and Illumina, but also demonstrates Mitalab's professional expertise, operational capability, and strong reputation in the healthcare and life sciences sector. Mitalab is committed to delivering a comprehensive Next-Generation Sequencing (NGS) ecosystem that simultaneously supports clinical applications, enhances diagnostic and treatment efficiency, and advances in-depth scientific research. As modern medicine and genomic technologies continue to play an increasingly vital role in healthcare, Mitalab's access to Illumina's advanced platforms will create new opportunities to improve the quality of medical diagnosis, laboratory services, and scientific research for hospitals, laboratories, research institutes, and the scientific community across Vietnam. This milestone is not only a source of pride for Mitalab, but also a strong motivation for Mitalabvn to continuously update and deliver cutting-edge medical technologies, contributing to the advancement of diagnostics, scientific innovation, and community healthcare. Once again, congratulations on this remarkable and meaningful partnership milestone.

PR Newswire
Apr 14th, 2026
Illumina and D3b unite 100,000 pediatric genomes to accelerate rare disease and cancer research

Illumina and the Center for Data-Driven Discovery in Biomedicine have announced a data partnership to advance paediatric cancer and rare disease research. D3b is analysing 100,000 whole genomes from paediatric patients using Illumina software solutions, creating one of the largest unified genomic datasets ever assembled. The resulting insights will be made available through the Gabriella Miller Kids First Data Resource Centre, enabling researchers and clinicians to uncover biological origins of rare diseases and cancers. The dataset includes whole genomes from patients with rare congenital conditions and cancers, analysed using DRAGEN v4.4 and Illumina Connected Analytics. Additionally, Illumina is supporting D3b in the Pediatric Care eXpansion programme, which aims to reduce patient care journeys from months to weeks through a national data exchange spanning over 200 US paediatric institutions.

Food Safety Magazine
Apr 13th, 2026
USDA-FSIS updates WGS laboratory method.

USDA-FSIS updates WGS laboratory method. April 13, 2026 The U.S. Department of Agriculture's Food Safety and Inspection Service (USDA-FSIS) has updated its whole genome sequencing (WGS) laboratory method to incorporate the Illumina MiSeq i100 sequencing platform. MiSeq i100 represents the next generation of MiSeq sequencing instrumentation featuring integrated sequencing chemistry and substantially reduced runtimes. FSIS reports that this modernization enhances its laboratory system's ability to generate consistent, high-quality genomic data with increased laboratory sample throughput. The updated Microbiology Laboratory Guidebook (MLG) chapter 42, "Whole Genome Sequencing of Bacterial Isolates," now includes protocols for using both the Illumina MiSeq and MiSeq i100 platforms. FSIS will begin integrating the MiSeq i100 platform starting in May 2026, through the remainder of the fiscal year as existing laboratory supplies are exhausted and additional i100 units come online across FSIS laboratories. The current MiSeq instrumentation remains fully valid and equivalent for WGS analyses and will continue to be used where appropriate. WGS determines the full DNA sequence of an organism in a single laboratory protocol, and FSIS performs WGS on every bacterial isolate obtained from regulated food product and environmental samples. This publicly available data supports foodborne pathogen monitoring, food safety research, and other regulatory applications. FSIS notes that the inclusion of a specific commercial product in the MLG should not be considered an endorsement by the agency. Looking for quick answers on food safety topics? Try Ask FSM, our new smart AI search tool. Ask FSM SPONSORED BY Hi there. I'm Ask FSM. You can ask me anything about science-based solutions f The Food Safety Magazine editorial team comprises Bailee Henderson, Digital Editor | and Adrienne Blume, M.A., Editorial Director. JOIN TODAY to unlock your recommendations. Already have an account? Sign In

Yahoo Finance
Apr 9th, 2026
Illumina shares up 31.7% since October despite declining organic revenue and mediocre ROIC

Illumina has gained 31.7% since October 2025, reaching $126.99 per share, outpacing the S&P 500's 1.8% decline. Despite this performance, analysts cite three concerns about the genomics company. Illumina's organic revenue has declined an average of 1.1% year-on-year over the past two years, suggesting weakness in its core business. The company's earnings per share grew just 1.5% annually over five years, below its 6% revenue growth, indicating decreasing profitability. Additionally, its five-year average return on invested capital of 0.3% falls below typical healthcare sector costs. Trading at 24.7× forward price-to-earnings, the stock may present excessive downside risk despite recent gains, according to the analysis.